Business Description
Tasly Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000001C81
Share Class Description:
SHSE:600535: Class ACompare
Compare
Traded in other countries / regions
600535.China IPO Date
2002-08-23Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.73 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 2.1 | |||||
| Interest Coverage | 18.23 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 5.34 | |||||
| Beneish M-Score | -3.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -13.6 | |||||
| 3-Year EBITDA Growth Rate | -7.2 | |||||
| 3-Year EPS without NRI Growth Rate | 12.8 | |||||
| 3-Year FCF Growth Rate | 11.7 | |||||
| 3-Year Book Growth Rate | 1.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.51 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.77 | |||||
| 9-Day RSI | 38.9 | |||||
| 14-Day RSI | 40.03 | |||||
| 6-1 Month Momentum % | 22.45 | |||||
| 12-1 Month Momentum % | 6.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 2.95 | |||||
| Cash Ratio | 2.01 | |||||
| Days Inventory | 211.26 | |||||
| Days Sales Outstanding | 34.11 | |||||
| Days Payable | 98.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.16 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| Forward Dividend Yield % | 2.16 | |||||
| 5-Year Yield-on-Cost % | 2.51 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | -3.04 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.8 | |||||
| Operating Margin % | 17.35 | |||||
| Net Margin % | 12.35 | |||||
| FCF Margin % | 21.98 | |||||
| ROE % | 8.65 | |||||
| ROA % | 6.24 | |||||
| ROIC % | 10.78 | |||||
| ROC (Joel Greenblatt) % | 25.54 | |||||
| ROCE % | 8.94 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21 | |||||
| PE Ratio without NRI | 20.16 | |||||
| Shiller PE Ratio | 16.99 | |||||
| Price-to-Owner-Earnings | 37.63 | |||||
| PS Ratio | 2.6 | |||||
| PB Ratio | 1.83 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| Price-to-Free-Cash-Flow | 11.7 | |||||
| Price-to-Operating-Cash-Flow | 8.67 | |||||
| EV-to-EBIT | 15.83 | |||||
| EV-to-Forward-EBIT | 15.09 | |||||
| EV-to-EBITDA | 15.83 | |||||
| EV-to-Forward-EBITDA | 13.15 | |||||
| EV-to-Revenue | 2.38 | |||||
| EV-to-Forward-Revenue | 2.27 | |||||
| EV-to-FCF | 10.96 | |||||
| Price-to-Projected-FCF | 0.93 | |||||
| Price-to-Median-PS-Value | 1.1 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 5.16 | |||||
| Price-to-Net-Cash | 56 | |||||
| Earnings Yield (Greenblatt) % | 6.32 | |||||
| FCF Yield % | 8.44 | |||||
| Forward Rate of Return (Yacktman) % | -7.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tasly Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 8,674.014 | ||
| EPS (TTM) (Â¥) | 0.72 | ||
| Beta | 1.23 | ||
| Volatility % | 30.29 | ||
| 14-Day RSI | 40.03 | ||
| 14-Day ATR (Â¥) | 0.420737 | ||
| 20-Day SMA (Â¥) | 15.7645 | ||
| 12-1 Month Momentum % | 6.55 | ||
| 52-Week Range (Â¥) | 12.88 - 18 | ||
| Shares Outstanding (Mil) | 1,493.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tasly Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tasly Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tasly Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Tasly Pharmaceutical Group Co Ltd(SHSE:600535)'s stock price today?
The current price of SHSE:600535 is ¥15.12. The 52 week high of SHSE:600535 is ¥18.00 and 52 week low is ¥12.88.
When is next earnings date of Tasly Pharmaceutical Group Co Ltd(SHSE:600535)?
The next earnings date of Tasly Pharmaceutical Group Co Ltd(SHSE:600535) is .
Does Tasly Pharmaceutical Group Co Ltd(SHSE:600535) pay dividends? If so, how much?
The Dividend Yield %  of Tasly Pharmaceutical Group Co Ltd(SHSE:600535) is 2.16% (As of Today), Highest Dividend Payout Ratio of Tasly Pharmaceutical Group Co Ltd(SHSE:600535) was 0.81. The lowest was 0.27. And the median was 0.44. The  Forward Dividend Yield % of Tasly Pharmaceutical Group Co Ltd(SHSE:600535) is 2.16%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers